25.1 C
New York
Sunday, July 3, 2022

Longeveron Inc. (LGVN) Stock Dropped After Hours Following the Expansion of is Leadership.

Longeveron Inc. (LGVN) is a biotechnology firm manufacturing cell therapies for specific life-threatening diseases with its investigational product LOMECEL-B. Its shares dipped by 9.73% to be $11.6 during Tuesday’s regular trading session. Its price dropped further as of the writing in the aftermarket session by 7.07%. The one-year price range of the shares is $2.84-$45.0 with a market cap of $242.5 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


LGVN: Leadership Expansion

LGVN reported on April 05 about the appointment of K. Chris Min to the company’s executive leadership portfolio as the new Chief Medical Officer with effect from April 4. He will lead international clinical projects and regulatory strategy of the company’s pipeline products, along with progression in Lomecel-B into pivotal stage studies and its approval. He brought ten years of clinical development experience and served at Enterin Inc. as the Head of Medical & Clinical Development and its Vice President.

LGVN: Industry Outlook

The biotechnology industry’s performance has been impacted by various factors in the last year as they became more volatile over the year. The analysts are suggesting an impact of ‘tourist investors’ as one of the reasons for the tumbling of biotech stocks. Another reason is the Russian hostility towards Ukraine. The financial experts are estimating that in the coming days, larger biopharma companies will acquire private and public sector biotechnology companies.

LGVN: Company Outlook

The company has recently published positive Phase 1 studies outcomes of LOMECEL-B for Alzheimer’s disease and dementia. It is a breakthrough for the company’s management. Also, it made appearances at certain medical and investor conferences in March 2022. Although, it missed the revenue expectations, yet surpassed the EPS estimations by $0.05.


LGVN stock performed outclass in the past six months as visible in its shares price rise. Its shares rose phenomenally by 252% during the past six months as the company’s research was published in several peer-reviewed journals. Its stock dropped on Tuesday after hours following the announcement of changes in its Executive leadership.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles